Peri-neural Electrical Dry Needling Migraine Treatment Study

Migraine Headache Clinical Trial

Official title:

A Randomized Controlled Crossover Study to Determine the Effectiveness of Peri-Neural Electrical Dry Needling (PNED) vs. Standard Care for the Treatment of Patients With Migraine Headaches

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04252391
• Other study ID #: WheatonFH
• Status: Recruiting
• Phase: N/A
• Start date: February 18, 2020
• Est. completion date: April 2023

Study information

• Verified date: May 2022
• Source: Wheaton Franciscan Healthcare
• Contact: Jackie Kirchen, MS, CIP
• Phone: 414-465-3134
• Email: jackie.kirchen[@]ascension.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study seeks to determine the effectiveness of a specific treatment protocol using dry needling with perineural electrical stimulation in comparison to standard treatment in physical therapy for patients with migraine headaches. This will be a randomized cross-over study in which participants will be in the first arm of the study, have a washout period, then cross over to the other arm of the study.

Description:

From current understanding of migraine pathophysiology, the investigators know that it involves excitability of the trigeminovascular system. Intercranial vasculature containing nociceptor innervation consists of unmyelinated (c-fibers) and thinly myelinated (a-delta fibers ) axons which hold vasoactive neuropeptides including substance P and (CGRP) calcitonin gene related peptide. When a migraine occurs, there is a cortical spreading depolarization, which on a molecular level involves a release of ATP, glutamate, potassium, hydrogen ions, glia or vascular cells, and CGRP and nitric oxide by activated perivascular nerves. These substances, including CGRP diffuse to come in contact with nociceptors causing neurogenic inflammation (vasodilation), thus propagating a headache. Electrical perineural dry needling causes the release of substance-P and CGRG predominantly from non-neural structures, facilitating a negative feedback loop to neural and neuroactive components of the target tissue. This causes a lowering of the levels of CGRP which in turn decreases the inflammatory component thought to play a role in migraine headaches.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: April 2023
• Est. primary completion date: April 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Men and women age 18 to 100 years old
• Acute or chronic manifestation of migraine headaches or prior diagnosis of migraine headache.
• Numeric pain rating of 3/10 (where 0= no pain and 10= worst pain)

Exclusion Criteria:

• History of epilepsy
• Needle-phobia
• Unstable psychological status
• Compromised immune system
• Metallic allergy
• Having not eaten within the past 3 hours
• Inability to lie in prone, or side-lying
• Pregnant or trying to become pregnant
• Inability to consent or understand English.
• Prisoners

Related Conditions & MeSH terms

• Headache
• Migraine Disorders
• Migraine Headache

Intervention

Procedure:
• Perineural electrical dry needling
Standard care plus use of perineural electrical dry needling involving use of a monofilament needle of 15 or 30 mm length, 0.25 mm diameter will be placed utilizing the therapist's dominant hand following palpation of correct needle location. An electrical stimulation unit will be used to conduct an electrical impulse. The unit used will be an ES-130 by ITO (Japan) using a DC 9V battery producing an asymmetrical biphasic waveform. The unit has 6 available leads with alligator clamps, connecting to needle shafts. Parameters of PNED will include intensity set at a strong yet comfortable setting according to patient feedback. Treatment duration will be 15 minutes. Treatment frequency will be set to Medium at level 8 (80 Hz). Parameters will be set to elicit a sensory response.
• Standard Care
cervical or thoracic manipulation or mobilization, muscle stretching, muscle strengthening, electrical trigger point dry needling , soft tissue release and prescribed therapeutic exercises .

Locations

Country	Name	City	State
United States	Ascension Rehabilitation Services	Milwaukee	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
Wheaton Franciscan Healthcare

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in numeric pain rating scale	Self reported pain intensity immediately before and after treatment using a numeric pain rating scale from 0 to 10 (0 = no pain and 10 = the worst pain).; Participants will be assessed 2 days per week with a minimum of 1 day between treatment days.	1-6 days
Primary	Change in Neck disability index scale	A functional status scale ranging from 0% to 100% (0%= no activity limitation, 100% =complete activity limitation).; Participants will be assessed immediately before and after treatment. Participants will be assessed 2 days per week with a minimum of 1 day between treatment days.	1-6 days
Secondary	Trends with use of perineural electrical dry needling with or without CGRP antagonist drugs.	Because this is a small trial it is unlikely that we will be able to determine if migraine drugs significantly modify the effect perineural electrical dry needle treatment has on pain and the neck disability index. However we will look for any trends in interaction between perineural electrical dry needle treatment and migraine drugs using exploratory data analysis and box plot comparisons.	following 4 weeks of treatment in the standard care plus perineural electrical dry needling arm.